New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
11:29 EDTACT, AKRXFTC approves settlement with Akorn over Hi-Tech Pharmacal acquisition
The Federal Trade Commission has approved a final order settling charges that Akorn Enterprises’ (AKRX) $640M acquisition of Hi-Tech Pharmacal was anticompetitive and would lead to higher prices for consumers in several current and future generic drug markets. The final order settling the FTC’s charges requires the parties to sell either Akorn’s or Hi-Tech’s rights and assets to each of five drug products to Watson Laboratories (ACT) and required Akorn to assign Watson its contract for making a currently available branded and generic topical anesthetic cream within 10 days after the deal is completed. Reference Link
News For AKRX;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for AKRX;ACT

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use